(Q42112624)

16 October 2017

Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease (English)

1 reference

16 October 2017

Babatunde O Oyajobi

1

1 reference

16 October 2017

I Ross Garrett

2

1 reference

16 October 2017

Anjana Gupta

3

1 reference

16 October 2017

Alda Flores

4

1 reference

16 October 2017

Javier Esparza

5

1 reference

16 October 2017

Steve Muñoz

6

1 reference

16 October 2017

Ming Zhao

7

1 reference

16 October 2017

Gregory R Mundy

8

1 reference

16 October 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

British Journal of Haematology

16 October 2017

1 reference

16 October 2017

139

1 reference

16 October 2017

434-438

1 reference

16 October 2017

3

1 reference

Bortezomib: proteasome inhibition as an effective anticancer therapy

16 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482356

Essential role of beta-catenin in postnatal bone acquisition

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482356

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482356

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482356

Method for determination of bone alkaline phosphatase activity: analytical performance and clinical usefulness in patients with metabolic and malignant bone diseases.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482356

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482356

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4482356

Assessing Bone Formation Using Mouse Calvarial Organ Cultures

1 December 2018

1 reference

12 December 2020

Biologic and therapeutic determinants of bone mineral density in multiple myeloma

1 reference

12 December 2020

A role for Wnt/beta-catenin signaling in lens epithelial differentiation

1 reference

12 December 2020

The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer

1 reference

12 December 2020

Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications

1 reference

12 December 2020

Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis

1 reference

12 December 2020

Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption

1 reference

12 December 2020

10.1111/J.1365-2141.2007.06829.X

Identifiers

DOI

1 reference

16 October 2017

1 reference

16 October 2017

1 reference